NCT00477464 - Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Metastatic Breast CancerNeoplasms, Breast

Interventions

DRUG

Lapatinib

1250mg once daily

DRUG

capecitabine

2000mg/m\^2 twice daily (14 days out of 21 days)

Trial Locations (15)

464-8681

GSK Investigational Site, Aichi

277-8577

GSK Investigational Site, Chiba

791-0280

GSK Investigational Site, Ehime

811-1395

GSK Investigational Site, Fukuoka

003-0804

GSK Investigational Site, Hokkaido

305-8576

GSK Investigational Site, Ibaraki

892-0833

GSK Investigational Site, Kagoshima

540-0006

GSK Investigational Site, Osaka

553-0003

GSK Investigational Site, Osaka

411-8777

GSK Investigational Site, Shizuoka

329-0498

GSK Investigational Site, Tochigi

104-0045

GSK Investigational Site, Tokyo

104-8560

GSK Investigational Site, Tokyo

113-8677

GSK Investigational Site, Tokyo

135-8550

GSK Investigational Site, Tokyo